The in vitro activities of ABT-773, azithromycin, erythromycin, and clindamycin were compared by testing 1,223 clinical isolates selected to represent different species and phenotypes. ABT-773 was particularly potent against staphylococci (the MIC at which 90% of the strains tested were inhibited [MIC 90 ] was <0.06 g/ml), including all strains that were macrolide resistant but clindamycin susceptible. Streptococcus pneumoniae and other streptococci were inhibited by low concentrations of ABT-773, and that included most erythromycinresistant strains. Against Haemophilus influenzae, ABT-773 and azithromycin were similar in their antibacterial potency (MIC 90 , 4.0 and 2.0 g/ml, respectively).
The ketolide class of antimicrobial agents includes 14-membered-ring macrolides that differ from erythromycin A in that they have a 3-keto group in place of the cladinose moiety in the macrolide ring. Telithromycin was the first ketolide to be developed for clinical use. ABT-773 is another ketolide that is currently being evaluated in phase III clinical trials. Both ketolides are active against gram-positive cocci, including all erythromycin-susceptible strains and most erythromycin-resistant strains (1, 3, 4, 6, 7) . Strains of Streptococcus pneumoniae which are macrolide resistant by virtue of erm or mef mechanisms are fully susceptible to ABT-773, because the drug concentrates within the bacterial cell, where it tightly binds to the ribosomes and subsequently inhibits protein synthesis (5) .
In the present study we evaluated the in vitro activity of ABT-773 compared to those of azithromycin, erythromycin, and clindamycin. Broth microdilution tests were performed according to the procedures defined by the National Committee for Clinical Laboratory Standards (NCCLS) (8) . The agar dilution method was used for testing Neisseria gonorrhoeae and Neisseria meningitidis isolates, and in that case, ABT-773 and erythromycin A were the only drugs tested. The clinical isolates in our stock culture collection were selected to represent different species and phenotypes. Table 1 describes the 1,223 isolates that were included in this evaluation. Those isolates were initially recovered from patients throughout North America, and most had been stored no longer than two years when this study was begun.
ABT-773 was very potent against macrolide-susceptible staphylococci (the MIC at which 90% of the strains tested were inhibited [MIC 90 ] was 0.06 g/ml versus 0.5 g/ml for erythromycin A). That in vitro activity was also seen with macrolideresistant strains that were susceptible to clindamycin. Staphylococci that were resistant to the macrolides and to clindamycin were not inhibited by the ketolide ABT-773 (MIC, Ͼ16 g/ml).
The other ketolide, telithromycin, has also been shown to have little activity against staphylococci with the macrolide-and lincosamide-resistant phenotype (3). That phenotype is not uncommon; i.e., Auckenthaler et al. (2) found that 15% of 1,465 clinical isolates of Staphylococcus aureus from 23 medical centers in 18 different countries had that phenotype, as did 30% of 667 coagulase-negative Staphylococcus spp. Clindamycin resistance was more common among oxacillin-resistant staphylococci (3% of oxacillin-susceptible S. aureus but 42% of oxacillin-resistant S. aureus). Only clindamycin-susceptible staphylococci might be expected to be clinically responsive to the ketolides, and that would include 97% of all oxacillin-susceptible S. aureus isolates, of which 82% would be susceptible to the macrolides (2).
The 317 S. pneumoniae strains that we tested included 75 penicillin-susceptible strains, 83 strains intermediately resistant to penicillin (penicillin intermediate), and 159 penicillinresistant strains. Half of the penicillin-resistant strains were resistant to erythromycin A, as were 29 of 83 (35%) penicillinintermediate strains. All S. pneumoniae isolates were susceptible to ABT-773 including clindamycin-and erythromycinresistant strains. The other ketolide, telithromycin, has also been shown to be active against all three phenotypes of pneumococci (4). The clindamycin-susceptible and erythromycinresistant phenotype is probably associated with an efflux mechanism that does not affect the ketolides (9) . The other species of streptococci included in the present study were inhibited by low concentrations of ABT-773, even though some were resistant to erythromycin A and to clindamycin. Although all streptococci were inhibited by Յ0.5 g of ABT-773 per ml, MICs for erythromycin-susceptible strains were consistently lower than those for erythromycin-resistant strains.
Many enterococci required relatively high concentrations of ABT-773 for inhibition; they were also relatively resistant to the other study drugs. More than half of the vancomycinsusceptible Enterococcus spp. were inhibited by low concentrations of ABT-773 (MIC, Յ0.03 g/ml), but the MIC 90 s were Ն4.0 g/ml. Most vancomycin-resistant enterococci were not inhibited by any of the study drugs at the highest concentrations tested. Telithromycin has also been shown to have similarly elevated MICs against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium (1, 3) . Against Haemophilus influenzae strains, the MIC 90 of ABT-773 was 4.0 g/ml, and its in vitro activity was not affected by ampicillin resistance or susceptibility. The proper interpretation of these MICs must await clinical response data. The other ketolide, telithromycin, has been found to have nearly identical MICs against H. influenzae (1, 3) .The MICs of both ketolides are only two times greater than those of azithromycin and one-half those of erythromycin A.
For the other gram-positive strains that were studied, the MICs of ABT-773 were lower than those of azithromycin or erythromycin A. The three species of gram-negative cocci that we tested were inhibited by low concentrations (Յ0.25 g/ml) of ABT-773; erythromycin A was less potent, but all MICs were Յ1.0 g/ml.
The potency of ABT-773 against susceptible staphylococci and pneumococci is particularly noteworthy, as is its activity against erythromycin-and azithromycin-resistant pneumococci. Provided that reasonable pharmacokinetic properties can be demonstrated and that there are no unexpected toxicity problems, ABT-773 should be a helpful addition to the list of antimicrobial agents that are available for treating communityacquired infections of the respiratory tract or skin and soft tissue, especially in communities where strains that are resistant to the macrolides are endemic.
